Engineered Bispecific Antibodies (BsAb) Novel Approaches
& Pipeline Insights, 2016” emphasizes on the novel bispecific antibodies
technologies in research and development. The report enlists company, target
antigens, phase and indication specific R&D pipelines of Bispecifc
Antibodies (bsAbs). It includes information about 18 companies with 41 products
in pipeline based on 19 different technologies. The report also covers other
commercial aspects such as the market assessment of the pipeline drugs, future
drugs approval timeline, current and future pipeline scenario. The report also
provides the detailed analysis on barriers and drivers.
Report
Highlights:
- Bispecific Antibodies Market Assessment
- Bispecific Antibodies Pipeline scenario
- Historical Technology timeline & Novel technologies
- Current Prominent Research Areas and Key Players
- Market Drivers and Barriers
Scope
- Overview of the global Bispecific antibodies pipeline and marketed scenario, products and associated companies information
- Coverage of global Bispecific antibody therapies under development
- Competitive landscape of products for key players and related indications
- Coverage of licensors, collaborators and Development partners
- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
- Highlights of Novel Bispecifc Antibodies technologies and innovative companies
- Key topics covered include strategic competitor assessment, barriers and drivers in the market
Spanning over 111 pages, “Engineered Bispecific Antibodies (BsAb) Novel Approaches
& Pipeline Insights, 2016” report covers Report
Introduction, Report Highlights, Scope, Market Drivers & Market Barriers,
Pipeline Scenario, Pipeline Profiles, Report Methodology.
For more information Visit at: http://mrr.cm/Jop
Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.